A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...
Kids and teenagers with spinal muscular atrophy had more mobility after receiving a single-dose gene replacement therapy, ...
Novartis’ Itvisma wins FDA approval as the first gene replacement therapy for spinal muscular atrophy (SMA) patients age 2 ...
The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access ...
A California toddler is the first person in the world to receive gene therapy to treat his devastating disease. Three-year-old Oliver Chu was born with a rare, genetic condition called Hunter syndrome ...
Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data ...
Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...
Oliver Chu was born with a rare genetic condition called Hunter syndrome that impacts physical and mental development. The toddler has now exceeded doctors' expectations after becoming the first ...
Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...
COLUMBUS, Ga. (WRBL) — September is Sickle Cell Awareness Month, and millions of people worldwide are living with the disease. But advances in treatment are being made. WRBL News 3 anchor Cameron ...
Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated for intrathecal administration across age groups.
Assistant Professor of Pharmaceutical Sciences KC Mei standing in his lab at the School of Pharmacy at Binghamton University, State University of New York. BINGHAMTON, N.Y. -- A pharmacy professor at ...